Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
J Ocul Pharmacol Ther ; 36(4): 208-228, 2020 05.
Article in English | MEDLINE | ID: mdl-32233938

ABSTRACT

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade extracellular matrix (ECM) components such as collagen and have important roles in multiple biological processes, including development and tissue remodeling, both in health and disease. The activity of MMPs is influenced by the expression of MMPs and tissue inhibitors of metalloproteinase (TIMPs). In the eye, MMP-mediated ECM turnover in the juxtacanalicular region of the trabecular meshwork (TM) reduces outflow resistance in the conventional outflow pathway and helps maintain intraocular pressure (IOP) homeostasis. An imbalance in the MMP/TIMP ratio may be involved in the elevated IOP often associated with glaucoma. The prostaglandin analog/prostamide (PGA) class of topical ocular hypotensive medications used in glaucoma treatment reduces IOP by increasing outflow through both conventional and unconventional (uveoscleral) outflow pathways. Evidence from in vivo and in vitro studies using animal models and anterior segment explant and cell cultures indicates that the mechanism of IOP lowering by PGAs involves increased MMP expression in the TM and ciliary body, leading to tissue remodeling that enhances conventional and unconventional outflow. PGA effects on MMP expression are dependent on the identity and concentration of the PGA. An intracameral sustained-release PGA implant (Bimatoprost SR) in development for glaucoma treatment can reduce IOP for many months after expected intraocular drug bioavailability. We hypothesize that the higher concentrations of bimatoprost achieved in ocular outflow tissues with the implant produce greater MMP upregulation and more extensive, sustained MMP-mediated target tissue remodeling, providing an extended duration of effect.


Subject(s)
Antihypertensive Agents/pharmacology , Bimatoprost/pharmacology , Glaucoma/drug therapy , Matrix Metalloproteinases/drug effects , Prostaglandins, Synthetic/pharmacology , Administration, Topical , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/therapeutic use , Bimatoprost/administration & dosage , Bimatoprost/therapeutic use , Ciliary Body/metabolism , Collagen/metabolism , Drug Implants , Extracellular Matrix/metabolism , Glaucoma/metabolism , Homeostasis/drug effects , Homeostasis/physiology , Humans , Intraocular Pressure/drug effects , Matrix Metalloproteinases/metabolism , Models, Animal , Prostaglandins, Synthetic/administration & dosage , Prostaglandins, Synthetic/therapeutic use , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/metabolism , Trabecular Meshwork/metabolism
2.
Acta Cir Bras ; 33(11): 945-953, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30517321

ABSTRACT

PURPOSE: To investigate the effect of oxymatrine on periodontitis in rats and related mechanism. Methods: Ninety SD rats were divided into control, model, 10, 20 and 40 mg/kg oxymatrine and tinidazole groups. The periodontitis model was established in later 5 groups. The 10, 20 and 40 mg/kg oxymatrine groups were intragastrically administrated with 10, 20 and 40 mg/kg oxymatrine, respectively. The tinidazole group was intragastrically administrated with 100 mg/kg tinidazole. The treatment duration was 4 weeks. The tooth mobility, gingival and plaque indexes, serum inflammatory factor levels and gingival tissue matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) protein levels were detected. Results: After treatment, compared with model group, in 40 mg/kg oxymatrine group the rat general conditions were obviously improved, the tooth mobility, gingival index and plaque index were significantly decreased (P<0.05), the serum tumor necrosis factor-α, interleukin-1ß and prostaglandin E2 levels were significantly decreased (P<0.05), the MMP-2 and MMP-9 protein levels were significantly decreased (P<0.05), and the TIMP-2 protein level was significantly increased (P<0.05). Conclusions: Oxymatrine can alleviate the experimental periodontitis in rats. The mechanism may be related to its inhibiting inflammatory factor secretion and regulating MMPs/TIMP protein expression.


Subject(s)
Alkaloids/pharmacology , Anti-Inflammatory Agents/pharmacology , Matrix Metalloproteinases/drug effects , Periodontitis/drug therapy , Quinolizines/pharmacology , Tissue Inhibitor of Metalloproteinases/drug effects , Animals , Dental Plaque Index , Dinoprostone/blood , Female , Gingiva/pathology , Interleukin-1beta/blood , Male , Matrix Metalloproteinases/analysis , Periodontitis/metabolism , Random Allocation , Rats, Sprague-Dawley , Reference Values , Reproducibility of Results , Tinidazole , Tissue Inhibitor of Metalloproteinases/analysis , Treatment Outcome , Tumor Necrosis Factor-alpha/blood
3.
Acta cir. bras ; 33(11): 945-953, Nov. 2018. tab, graf
Article in English | LILACS | ID: biblio-973475

ABSTRACT

Abstract Purpose: To investigate the effect of oxymatrine on periodontitis in rats and related mechanism. Methods: Ninety SD rats were divided into control, model, 10, 20 and 40 mg/kg oxymatrine and tinidazole groups. The periodontitis model was established in later 5 groups. The 10, 20 and 40 mg/kg oxymatrine groups were intragastrically administrated with 10, 20 and 40 mg/kg oxymatrine, respectively. The tinidazole group was intragastrically administrated with 100 mg/kg tinidazole. The treatment duration was 4 weeks. The tooth mobility, gingival and plaque indexes, serum inflammatory factor levels and gingival tissue matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) protein levels were detected. Results: After treatment, compared with model group, in 40 mg/kg oxymatrine group the rat general conditions were obviously improved, the tooth mobility, gingival index and plaque index were significantly decreased (P<0.05), the serum tumor necrosis factor-α, interleukin-1β and prostaglandin E2 levels were significantly decreased (P<0.05), the MMP-2 and MMP-9 protein levels were significantly decreased (P<0.05), and the TIMP-2 protein level was significantly increased (P<0.05). Conclusions: Oxymatrine can alleviate the experimental periodontitis in rats. The mechanism may be related to its inhibiting inflammatory factor secretion and regulating MMPs/TIMP protein expression.


Subject(s)
Animals , Male , Female , Periodontitis/drug therapy , Quinolizines/pharmacology , Tissue Inhibitor of Metalloproteinases/drug effects , Matrix Metalloproteinases/drug effects , Alkaloids/pharmacology , Anti-Inflammatory Agents/pharmacology , Periodontitis/metabolism , Reference Values , Tinidazole , Dinoprostone/blood , Random Allocation , Dental Plaque Index , Reproducibility of Results , Tumor Necrosis Factor-alpha/blood , Treatment Outcome , Rats, Sprague-Dawley , Tissue Inhibitor of Metalloproteinases/analysis , Matrix Metalloproteinases/analysis , Interleukin-1beta/blood , Gingiva/pathology
4.
Afr Health Sci ; 16(2): 542-53, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27605970

ABSTRACT

BACKGROUND: Recombinant human endostatin (Endostar) has been widely used to suppress angiogenesis in carcinoma patients. Hypertrophic scar (HS) tissue, much like a carcinoma, is often associated with angiogenesis. However, there have been few studies conducted on the effects of Endostar on HS or its mechanism. OBJECTIVE: This paper investigated the effects Endostar on the HS of rabbit ears and studied the effects of Endostar on VEGF and TIMP-1 expression. METHODS: Sixteen New Zealand white rabbits were used to establish HS models. Then, rabbit ears containing HS were randomly assigned to either the Endostar group or the control group. The changes of appearance and histology were evaluated using the naked eye, hematoxylin eosin staining, and a scar elevation index. The VEGF and TIMP-1 expressions were detected by immunohistochemical staining, RT-PCR, and western blot. RESULTS: The thickness of the connective tissue in the Endostar group were thinner, the numbers of micro vessels and fibroblasts were fewer, and the collagen fibers were smoother. Moreover, the mRNA and protein expressions of VEGF and TIMP-1 in the Endostar group were significantly lower than those in the control group. CONCLUSION: The results suggested that Endostar reduced the formation of HS by down-regulation of VEGF and TIMP-1 expressions.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Cicatrix, Hypertrophic/drug therapy , Endostatins/therapeutic use , Tissue Inhibitor of Metalloproteinases/drug effects , Vascular Endothelial Growth Factor A/drug effects , Animals , Biopsy, Needle , Cicatrix, Hypertrophic/genetics , Cicatrix, Hypertrophic/pathology , Disease Models, Animal , Down-Regulation , Ear, External/drug effects , Immunohistochemistry , Male , Rabbits , Random Allocation , Treatment Outcome
5.
Osteoarthritis Cartilage ; 24(2): 325-34, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26327449

ABSTRACT

OBJECTIVE: Norepinephrine (NE) was measured in synovial fluid of trauma patients and sympathetic nerve fibers were detected in healthy and osteoarthritic (OA) joint tissues indicating that cartilage pathophysiology might be influenced by sympathetic neurotransmitters. The aim of this study was to elucidate the mostly unknown role of NE in OA chondrocyte metabolism and inflammatory responses. METHODS: Articular cartilage was received after total knee replacement surgery from OA patients. Expression of adrenergic receptors (AR) and tyrosine hydroxylase (TH) was tested with end point polymerase chain reaction (PCR) and immunohistochemistry. 3-dimensional (3D) cell cultures were employed to analyze effects of NE on chondrocyte cell metabolism and the expression of interleukins (ILs), matrix metalloproteases (MMPs), tissue inhibitor of metalloproteases (TIMPs), glycosaminoglycan (GAG) and collagen II under non- and inflammatory conditions. Chondrocyte monolayer cultures were used to specify AR subtypes, to analyze cell cycle distribution and to determine catecholamines in cell culture supernatants. RESULTS: AR subtypes and TH were detected in chondrocytes, whereas NE was not released in measurable amounts. 10(-6) M NE reversed IL-1ß induced changes in IL-8, MMP-13, GAG and collagen II expression/production indicating for ß-AR signaling. Additionally, NE caused cell cycle slow down and decreased proliferation via ß-AR signaling. 10(-8) M NE increased the number of proliferating cells and induced apoptosis via α1-AR signaling. CONCLUSIONS: NE affects chondrocytes from OA cartilage regarding inflammatory response and its cell metabolism in a dose dependent manner. The sympathetic nervous system (SNS) may have a dual function in OA pathology with preserving a stable chondrocyte phenotype via ß-AR signaling and OA pathogenesis accelerating effects via α-AR signaling.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Chondrocytes/drug effects , Matrix Metalloproteinases/drug effects , Norepinephrine/pharmacology , Osteoarthritis, Knee/metabolism , Receptors, Adrenergic/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Tyrosine 3-Monooxygenase/drug effects , Aged , Aged, 80 and over , Cartilage, Articular/cytology , Cell Culture Techniques , Chondrocytes/immunology , Chondrocytes/metabolism , Collagen Type II/drug effects , Collagen Type II/metabolism , Female , Glycosaminoglycans/metabolism , Humans , Immunohistochemistry , Inflammation , Interleukin-1beta/pharmacology , Interleukin-8/drug effects , Interleukin-8/immunology , Interleukins/immunology , Knee Joint/cytology , Male , Matrix Metalloproteinase 13/drug effects , Matrix Metalloproteinase 13/metabolism , Matrix Metalloproteinases/metabolism , Middle Aged , Osteoarthritis, Knee/immunology , Polymerase Chain Reaction , Receptors, Adrenergic/metabolism , Receptors, Adrenergic, alpha/drug effects , Receptors, Adrenergic, alpha/metabolism , Receptors, Adrenergic, beta/drug effects , Receptors, Adrenergic, beta/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Tyrosine 3-Monooxygenase/metabolism
6.
Cancer Treat Rev ; 40(6): 730-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24767837

ABSTRACT

Prostate cancer is one of the most common malignancies affecting men worldwide, with bone being the most common site of metastasis in patients that progress beyond organ confinement. Bone metastases are virtually incurable and result in significant disease morbidity and mortality. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Several attractive molecules or pathways have been identified as new potential therapeutic targets for bone metastases caused by metastatic castration-resistant prostate cancer. In this review, we present the recent advances in molecular targeted therapies for prostate cancer bone metastasis focusing on therapies that target the bone cells and the bone microenvironment. The therapies covered in this review include agents that inhibit bone resorption, agents that stimulate bone formation, and agents that target the bone matrix. Suggestions to devise more effective molecular targeted therapies are proposed. Hopefully, with better understanding of the biology of the disease and the development of more robust targeted therapies, the survival and quality of life of the affected individuals could be significantly improved.


Subject(s)
Antineoplastic Agents/therapeutic use , Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Bone Resorption/prevention & control , Diphosphonates/therapeutic use , Molecular Targeted Therapy , Prostatic Neoplasms/pathology , RANK Ligand/drug effects , Animals , Bone Resorption/drug therapy , Cathepsin K/drug effects , Cathepsin K/metabolism , Disease Models, Animal , Humans , Male , Molecular Targeted Therapy/methods , Molecular Targeted Therapy/trends , Osteogenesis/drug effects , RANK Ligand/metabolism , Radioisotopes/therapeutic use , Signal Transduction/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/metabolism , Transforming Growth Factor beta/drug effects , Transforming Growth Factor beta/metabolism
7.
Br J Anaesth ; 106(5): 650-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21447487

ABSTRACT

BACKGROUND: Propofol is known to protect the myocardium against ischaemia/reperfusion (I/R) injury through its antioxidant and anti-inflammatory properties. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cell migration and invasion, and mediate tissue remodelling during I/R injury. They are regulated by various mechanisms including oxidative stress and AKT and ERK pathways. We investigated whether propofol affected the expression of MMPs and subsequent cell migration and invasion and the signalling pathways involved in primary rat cardiac fibroblasts undergoing hypoxia and reoxygenation. METHODS: The phosphorylation of ERK and AKT signalling pathways was examined by western blot analysis in rat primary cardiac fibroblasts after hypoxia and reoxygenation. mRNA expression of MMP and TIMPS was analysed by real-time PCR, and proteolytic activities of MMP-2 and -9 were assessed. The effects of propofol on migration, invasion, wound healing, and cell proliferation activity were evaluated after reoxygenation. RESULTS: Propofol induced AKT and ERK1/2 activation. Subsequent activation of MMPs resulted in increased cell migration, invasion, and wound-healing activity under hypoxia-reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) in rat cardiac fibroblasts. However, propofol had no effect on proliferation or viability of cardiac fibroblasts after hypoxia-reoxygenation. CONCLUSIONS: Propofol affected the expression of MMPs and TIMPs and subsequently induced cell migration and invasive ability, through activation of the ERK and AKT signalling pathway in hypoxia-reoxygenated rat cardiac fibroblasts.


Subject(s)
Anesthetics, Intravenous/pharmacology , Cell Hypoxia , Matrix Metalloproteinases/drug effects , Myocardial Reperfusion Injury/enzymology , Propofol/pharmacology , Animals , Cardiotonic Agents/pharmacology , Cell Hypoxia/physiology , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Extracellular Signal-Regulated MAP Kinases/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Fibroblasts/drug effects , Fibroblasts/enzymology , Gene Expression Regulation, Enzymologic/drug effects , Matrix Metalloproteinases/biosynthesis , Matrix Metalloproteinases/genetics , Myocardial Reperfusion Injury/pathology , Proto-Oncogene Proteins c-akt/drug effects , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Tissue Inhibitor of Metalloproteinases/biosynthesis , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/genetics
8.
J Periodontol ; 82(7): 1071-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21142980

ABSTRACT

BACKGROUND: Members of the matrix metalloproteinase (MMP) family have been shown to be involved in periodontal disease. Risk factors for periodontal disease include tobacco smoking. Cigarette smoke condensate (CSC) is comprised of thousands of chemicals. Nicotine is one of the active components in tobacco. This study compares the effects of CSC and nicotine at the level in CSC on the collagen-degrading ability of human gingival fibroblasts (HGFs) and the expression of selected MMPs and tissue inhibitors of metalloproteinases (TIMPs). METHODS: HGFs were seeded in six-well collagen-coated plates, exposed to 100 µg/mL (2.4 µg/mL nicotine) of CSC or 2.4 µg/mL nicotine for 3 days, and then collagen degradation was analyzed. After 3 days exposure to CSC or nicotine, the conditioned media from HGFs was collected and the membrane proteins were extracted for gelatin zymography and Western blot analyses. The mRNA levels of MMP-2, MMP-14, and TIMP-2 were measured by reverse transcription-polymerase chain reaction. RESULTS: The CSC increased collagen degradation, and increased the levels of TIMP-2, MMP-14, and the active MMP-2 in the membrane extracts, and their mRNA levels. CSC also increased the level of active MMP-2 in the conditioned media. Nicotine at the level in CSC (2.4 µg/mL) had little influence on collagen degradation, as well as on the protein and mRNA levels of MMP-2, MMP-14, and TIMP-2. CONCLUSIONS: CSC may increase HGF-mediated collagen degradation by affecting membrane-associated MMPs and TIMPs.


Subject(s)
Collagen Type I/drug effects , Fibroblasts/drug effects , Gingiva/drug effects , Nicotiana , Nicotine/pharmacology , Smoke , Blotting, Western , Cells, Cultured , Collagen Type I/analysis , Complex Mixtures/pharmacology , Culture Media, Conditioned , Culture Media, Serum-Free , Cyclophilins/analysis , Cyclophilins/drug effects , Enzyme Precursors/analysis , Enzyme Precursors/drug effects , Fibroblasts/metabolism , Gelatinases/analysis , Gelatinases/drug effects , Gingiva/cytology , Humans , Matrix Metalloproteinase 14/analysis , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinases, Membrane-Associated/analysis , Matrix Metalloproteinases, Membrane-Associated/drug effects , Protease Inhibitors/analysis , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-2/analysis , Tissue Inhibitor of Metalloproteinase-2/drug effects , Tissue Inhibitor of Metalloproteinases/analysis , Tissue Inhibitor of Metalloproteinases/drug effects
9.
J Periodontol ; 81(11): 1663-74, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20681807

ABSTRACT

BACKGROUND: Bone morphogenetic protein (BMP)-7 is a potent bone-inducing factor and was shown to promote periodontal regeneration in vivo and in vitro; however, to our knowledge, the specific effect of BMP-7 on cementoblasts has not been defined. We aimed to investigate the effects of BMP-7 on cementoblasts, which are cells responsible for tooth root-cementum formation. We hypothesized that BMP-7 would regulate mineralized tissue-associated genes in cementoblasts and influence the expression profile of genes associated with cementoblast extracellular matrix (ECM) and cell adhesion molecules (CAMs). METHODS: A murine immortalized cementoblast cell line (OCCM.30) was cultured with and without 50 ng/ml BMP-7. After 72 hours, total RNA was isolated, and mRNA levels for bone/cementum markers, including bone sialoprotein (BSP), osteocalcin (OCN), osteopontin (OPN), and runt-related transcription factor-2 (Runx2), were investigated by real-time quantitative reverse transcription-polymerase chain reaction (Q-PCR). In vitro mineral nodule formation was assayed on day 8 using von Kossa staining. A pathway-specific gene-expression array was used to determine BMP-7-responsive ECM and CAM genes in cementoblasts. RESULTS: Mineralized tissue markers were strongly regulated by BMP-7, with an almost three-fold increase in BSP and OCN transcripts and significant increases in OPN and Runx2 mRNA expressions. BMP-7 treatment markedly stimulated cementoblast-mediated biomineralization in vitro compared to untreated cells at day 8. BMP-7 treatment altered the OCCM.30 expression profile for ECM and CAM functional gene groups. BMP-7 tended to increase the expression of collagens and matrix metalloproteinases (MMPs), mildly decreased tissue inhibitors of MMPs (TIMPs), and had mixed regulatory effects on integrins. Using Q-PCR, selected array results were confirmed, including a significant BMP-7-induced increase in MMP-3 and a decrease in TIMP-2 mRNA expression. CONCLUSION: These results support the promising applications of BMP-7 in therapies aimed at regenerating periodontal tissues lost as a consequence of disease.


Subject(s)
Bone Morphogenetic Protein 7/pharmacology , Dental Cementum/drug effects , Animals , Calcification, Physiologic/drug effects , Cell Adhesion Molecules/drug effects , Cell Differentiation/drug effects , Cell Line , Collagen/drug effects , Core Binding Factor Alpha 1 Subunit/drug effects , Dental Cementum/cytology , Extracellular Matrix Proteins/drug effects , Gene Expression Profiling , Gene Expression Regulation/drug effects , Integrins/drug effects , Matrix Metalloproteinase 3/drug effects , Matrix Metalloproteinases/drug effects , Mice , Osteocalcin/drug effects , Osteopontin/drug effects , Protein Array Analysis , Time Factors , Tissue Inhibitor of Metalloproteinase-2/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Tooth Root/cytology , Tooth Root/drug effects , Up-Regulation
10.
J Asian Nat Prod Res ; 12(5): 388-98, 2010 May.
Article in English | MEDLINE | ID: mdl-20496196

ABSTRACT

Liver fibrosis results from chronic liver injury in conjunction with the accumulation of extracellular matrix proteins. The present study was performed to estimate the effect of bicyclol on bovine serum albumin (BSA)-induced immunological liver fibrosis in rats. Bicyclol (1) (100, 200, and 300 mg/kg) was given to rats by oral administration once a day for 5 weeks from the fourth week of intravenous injection of BSA. Blood and liver tissues were collected for the measurement of hydroxyproline (Hyp), procollagen type III (PIIIP), hyaluronic acid (HA), and transforming growth factor beta-1 (TGF-beta1) levels and liver pathological changes. The mRNA and protein expressions of hepatic TGF-beta1, interleukin-1 (IL-1), IL-10, MMP-2, TIMP-1, phosphorylated p38 (Pp38), and Smad2/3 were detected by reverse transcription polymerase chain reaction and Western blot. As a result, bicyclol significantly protected against BSA-induced liver fibrosis as evidenced by the reduction of elevated serum HA, PIIIP, and hepatic Hyp in rats, while liver pathological changes were also alleviated. The overexpressions of hepatic TGF-beta1, IL-1beta, IL-10, MMP-2, and TIMP-1 were suppressed by bicyclol in BSA-treated rats. The phosphorylations of Pp38 and Smad2/3 were also inhibited after bicyclol treatment. The hepatoprotection of bicyclol was mainly due to the modulation on the expression of inflammatory/anti-inflammatory cytokines, downregulation of hepatic TGF-beta1, and inhibition of hepatic collagen synthesis.


Subject(s)
Biphenyl Compounds/pharmacology , Liver Cirrhosis , Liver/drug effects , Serum Albumin, Bovine/pharmacology , Alanine Transaminase/analysis , Animals , Aspartate Aminotransferases/analysis , Biphenyl Compounds/chemistry , Dose-Response Relationship, Drug , Liver Cirrhosis/chemically induced , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Male , Matrix Metalloproteinase 2/drug effects , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Sequence Homology, Nucleic Acid , Tissue Inhibitor of Metalloproteinases/drug effects , Transforming Growth Factor beta1/drug effects , Transforming Growth Factor beta1/metabolism
11.
Acta Diabetol ; 47(2): 105-11, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19404565

ABSTRACT

Pericyte survival in diabetic retinopathy depends also on interactions with extracellular matrix (ECM) proteins, which are degraded by matrix metalloproteinases (MMP). Elevated glucose influences ECM turnover, through expression of MMP and their tissue inhibitors, TIMP. We reported on reduced pericyte adhesion to high glucose-conditioned ECM and correction by thiamine. We aimed at verifying the effects of thiamine and benfotiamine on MMP-2, MMP-9 and TIMP expression and activity in human vascular cells with high glucose. In HRP, MMP-2 activity, though not expression, increased with high glucose and decreased with thiamine and benfotiamine; TIMP-1 expression increased with high glucose plus thiamine and benfotiamine; MMP-9 was not expressed. In EC, MMP-9 and MMP-2 expression and activity increased with high glucose, but thiamine and benfotiamine had no effects; TIMP-1 expression was unchanged. Neither glucose nor thiamine modified TIMP-2 and TIMP-3 expression. TIMP-1 concentrations did not change in either HRP or EC. High glucose imbalances MMP/TIMP regulation, leading to increased ECM turnover. Thiamine and benfotiamine correct the increase in MMP-2 activity due to high glucose in HRP, while increasing TIMP-1.


Subject(s)
Glucose/pharmacology , Matrix Metalloproteinases/metabolism , Thiamine/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Cells, Cultured , DNA Primers , Humans , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinases/drug effects , Pericytes/cytology , Pericytes/drug effects , Pericytes/enzymology , RNA, Messenger/genetics , Retina/enzymology , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinases/drug effects
12.
Eur J Clin Invest ; 39(12): 1082-90, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19811527

ABSTRACT

BACKGROUND: Maternal diabetes is associated with morphological placental abnormalities and foeto-placental impairments. These alterations are linked with a dysregulation of the activity of matrix metalloproteinases (MMPs). We investigated the action of 15deoxyDelta(12,14) prostaglandin J(2) (15dPGJ(2)), a natural ligand of the peroxisome proliferator activated receptor (PPAR) gamma, on MMP-2 and MMP-9 activities and tissue inhibitors of matrix metalloproteinases (TIMP) levels in foetuses and placentas from diabetic rats. MATERIALS AND METHODS: Diabetes was induced in rat neonates by a single streptozotocin administration (90 mg kg(-1) s.c.). At 13.5 days of gestation, foetal and placental homogenates were prepared for the determination of PPARgamma levels (western blot) and 15dPGJ(2) concentration (enzyme-immunoassay), whereas the in vitro effect of 15dPGJ(2) (2 microM) was evaluated on placental and foetal MMPs and TIMP activities (zymography and reverse zymography), nitrate/nitrite concentrations (Griess method) and thiobarbituric acid reactive substances (TBARS). RESULTS: PPARgamma was increased while 15dPGJ(2) was decreased in placentas and foetuses from diabetic rats. 15dPGJ(2) additions were able to reduce the high activities of MMP-2 and MMP-9 present in diabetic placental tissues. 15dPGJ(2) additions reduced MMP-2 activity in control and diabetic foetuses. TIMP-3 levels were decreased in diabetic placentas and 15dPGJ(2) was able to enhance them to control values. Nitrates/nitrites and TBARS, metabolites of MMPs activators, were increased in the diabetic placenta and reduced by 15dPGJ(2). CONCLUSIONS: This study demonstrates that 15dPGJ(2) is a potent modulator of the balance between MMP activities and TIMP levels, which is needed in the correct formation and function of the placenta and foetal organs.


Subject(s)
Diabetes Mellitus/metabolism , Fetus/drug effects , Matrix Metalloproteinases/drug effects , PPAR gamma/antagonists & inhibitors , Placenta/drug effects , Prostaglandin D2/analogs & derivatives , Animals , Diabetes Mellitus/enzymology , Disease Models, Animal , Female , Fetus/metabolism , Gelatinases/metabolism , Matrix Metalloproteinases/metabolism , Nitric Oxide/metabolism , PPAR gamma/metabolism , Placenta/metabolism , Pregnancy , Prostaglandin D2/metabolism , Prostaglandin D2/pharmacology , Rats , Rats, Wistar , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/metabolism
13.
J Periodontal Res ; 44(6): 794-802, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19602122

ABSTRACT

BACKGROUND AND OBJECTIVES: In this study, we investigated the effect of basic fibroblast growth factor (bFGF) and dexamethasone (Dex) on mRNA expressions of collagen (COL) type I, III and X, matrix metalloproteinases (MMP)-1, -2, -3 and -9 and tissue inhibitors of metalloproteinases (TIMP)-1 and -2, and also on mineralization and morphology of periodontal ligament (PDL) cells. MATERIAL AND METHODS: Periodontal ligament cells were obtained from premolar teeth extracted for orthodontic reasons. Periodontal ligament cells were cultured with Dulbecco's modified Eagle's medium containing: (1) 5% fetal bovine serum (FBS); (2) 5% FBS + ascorbic acid (AA, 50 microg/mL); (3) 5% FBS + Dex (10(-7) m) + AA; (4) 5% FBS + bFGF (10 ng/mL) + AA; or (5) 5% FBS + Dex (10(-7) m) + bFGF + AA. Cells within each group were evaluated for gene expression profile using semi-quantitative reverse transcriptase-polymerase chain reaction for COL I, III and X, MMP-1, -2, -3 and -9 and TIMP-1 and -2 on days 14 and 21 and for biomineralization by von Kossa stain in vitro on day 21. Images of PDL cells were examined using a phase contrast microscope. RESULTS: Basic fibroblast growth factor stimulated MMP-1, MMP-3 and MMP-9 mRNA expressions and inhibited TIMP-2 mRNA expression. Treatment of cells with Dex + bFGF led to downregulation of MMP-1, MMP-3 and MMP-9 transcripts. Whilst AA alone and Dex alone induced biomineralization of PDL cells, bFGF blocked the mineralization activity of the cells. In the Dex + bFGF group, more mineral nodules were noted when compared to AA alone and Dex alone groups. CONCLUSION: The addition of Dex to culture reversed bFGF-mediated inhibition of mineralization. Use of combined bFGF and Dex to regulate PDL cell function may be a good therapeutic option to obtain periodontal regeneration.


Subject(s)
Dexamethasone/pharmacology , Fibroblast Growth Factor 2/pharmacology , Glucocorticoids/pharmacology , Matrix Metalloproteinases/drug effects , Periodontal Ligament/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Calcification, Physiologic/drug effects , Cell Shape/drug effects , Cells, Cultured , Collagen Type I/drug effects , Collagen Type III/drug effects , Collagen Type X/drug effects , DNA/drug effects , Down-Regulation , Gene Expression Profiling , Humans , Matrix Metalloproteinase 1/drug effects , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 3/drug effects , Matrix Metalloproteinase 9/drug effects , Periodontal Ligament/cytology , RNA, Messenger/drug effects , Tissue Inhibitor of Metalloproteinase-1/drug effects , Tissue Inhibitor of Metalloproteinase-2/antagonists & inhibitors , Tissue Inhibitor of Metalloproteinase-2/drug effects
14.
J Ethnopharmacol ; 120(1): 25-35, 2008 Oct 30.
Article in English | MEDLINE | ID: mdl-18761069

ABSTRACT

AIM OF THE STUDY: Guizhi-Fuling-decoction (GZFLD), a traditional Chinese medical formulation, exerts an anti-tumor effect, but the mechanisms of its action on invasive tumor inhibition have not been documented. The aims of this study were to identify the inhibitory effect of GZFLD on the invasive of cervical cancer and to elucidate the extensional mechanisms of its action. MATERIALS AND METHOD: The invasive ability of HeLa cells was tested with Transwell chamber. The expressions and activities of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) were measured by zymography/reverse zymography, RT-PCR and Western blot analysis. Establish tumor-bearing mice model to assess the ability of GZFLD to inhibit tumor growth and angiopoiesis in vivo. RESULTS: We have found that GZFLD suppressed the invasive ability of HeLa cells, inhibited MMPs expressions and activities, increased TIMPs expressions and activities, and furthermore restored the MMPs-TIMPs balance in HeLa cells in a concentration-dependent manner. Meanwhile in vivo, GZFLD had significantly inhibited tumor growth and angiopoiesis. CONCLUSION: In general, our results showed that GZFLD had inhibited the invasion of cervical cancer both in vitro and vivo. The inhibitory effects may be associated with restoring the MMPs-TIMPs balance, and then suppressing the degradation of extracellular matrix.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Drugs, Chinese Herbal/pharmacology , Matrix Metalloproteinases/drug effects , Uterine Cervical Neoplasms/drug therapy , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Blotting, Western , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/administration & dosage , Female , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Humans , Matrix Metalloproteinases/metabolism , Mice , Mice, Nude , Neoplasm Invasiveness , Neovascularization, Pathologic/drug therapy , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/metabolism , Uterine Cervical Neoplasms/pathology , Xenograft Model Antitumor Assays
15.
Synapse ; 62(8): 590-600, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18509851

ABSTRACT

Antidepressants induce structural remodeling in the adult hippocampus, including changes in dendritic arbors, axonal sprouting, neurogenesis, and endothelial cell proliferation. Such forms of structural plasticity take place in the context of the extracellular matrix environment and are known to be regulated by matrix metalloproteinases (MMPs), in particular MMP-2/9, and their endogenous regulators, the tissue inhibitors of the metalloproteinases (TIMPs 1-4). Given the hippocampal structural remodeling associated with antidepressant treatments, we hypothesized that antidepressants may regulate the expression and activity of MMP-2/9 and TIMPs 1-4. The influence of distinct classes of antidepressants, namely, electroconvulsive seizure, fluoxetine, tranylcypromine, and desipramine, on the gene expression of MMP-2, MMP-9, and TIMPs 1-4 in the hippocampus was determined using radioactive in situ hybridization. In addition, zymography studies addressed the regulation of the gelatinase activity of MMP-2/9 following acute and chronic antidepressant administration. We observed that acute and chronic ECS differentially regulate the transcript levels of MMP-2/9 and TIMPs 1-4 and also increase gelatinase activity in the hippocampus. Acute and chronic pharmacological antidepressants on the other hand differentially alter the expression of the TIMPs without any observed effect on hippocampal MMP-2/9 expression or activity. These findings raise the possibility that extracellular matrix modifying enzymes and their endogenous regulators may serve as targets for antidepressant treatments and suggests the possibility that they may contribute to antidepressant-mediated structural plasticity in the hippocampus.


Subject(s)
Antidepressive Agents/pharmacology , Hippocampus/drug effects , Hippocampus/enzymology , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 9/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Animals , Desipramine/pharmacology , Drug Administration Schedule , Electroconvulsive Therapy , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Fluoxetine/pharmacology , Male , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Tissue Inhibitor of Metalloproteinases/genetics , Tissue Inhibitor of Metalloproteinases/metabolism , Tranylcypromine/pharmacology
16.
J Periodontal Res ; 42(3): 228-35, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17451542

ABSTRACT

BACKGROUND AND OBJECTIVE: The objective of this study was to determine the effects that nicotine and the combination of nicotine and Porphyromonas gingivalis supernatant have on human gingival fibroblast-mediated collagen degradation. MATERIAL AND METHODS: Human gingival fibroblasts were cultured with 25-500 microg/ml of nicotine in collagen-coated six-well plates. On days 1-5, the conditioned media was collected for zymography and western blot analyses of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The cells were then removed and the collagen cleavage visualized by Coomassie blue staining. To examine the combined effect, 250 microg/ml of nicotine and 10% v/v culture supernatant of P. gingivalis ATCC 33277 were added to the human gingival fibroblasts. The mRNA levels of multiple MMPs and TIMPs were monitored. RESULTS: Nicotine increased the human gingival fibroblast-mediated collagen cleavage. The MMP-14 and MMP-2 produced by the nicotine-treated human gingival fibroblasts more readily underwent zymogen activation. Nicotine treatment resulted in TIMP-2 redistribution to the cell surface. The mRNAs of multiple MMPs and TIMPs were unaltered by nicotine. An additive collagen cleavage effect was observed when the human gingival fibroblasts were treated with both nicotine and P. gingivalis. CONCLUSION: Nicotine increased human gingival fibroblast-mediated collagen degradation, in part through the activation of membrane-associated MMPs. Nicotine and P. gingivalis had an additive effect on human gingival fibroblast-mediated collagen degradation.


Subject(s)
Fibroblasts/drug effects , Ganglionic Stimulants/adverse effects , Gingiva/drug effects , Nicotine/adverse effects , Porphyromonas gingivalis/metabolism , Blotting, Western/methods , Cells, Cultured/drug effects , Collagen/drug effects , Fibroblasts/enzymology , Gingiva/cytology , Humans , Matrix Metalloproteinases/drug effects , Matrix Metalloproteinases/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Tissue Inhibitor of Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/metabolism
17.
Am J Nephrol ; 27(3): 221-5, 2007.
Article in English | MEDLINE | ID: mdl-17384500

ABSTRACT

BACKGROUND: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play an important role in the atherosclerosis. Recombinant human erythropoietin (EPO) has become widely used to treat anemic hemodialyzed (HD) patients; however, an increased mortality has been reported for HD patients with cardiovascular disease when randomly assigned to normal hematocrit by EPO. Therefore, we conducted a study examining the effect of EPO on MMPs/TIMPs system, oxidative stress and inflammation in these patients. METHODS: Assessment of MMP-2, MMP-9, TIMP-1 and TIMP-2 were performed in 20 stable HD patients and 15 healthy controls. Additionally, the effects of EPO on malondialdehyde (MDA)--a marker of SOX and C-reactive protein (CRP) levels--as a marker of inflammation were also investigated. Of the 20 patients, 10 were receiving EPO therapy [HD-EPO(+)] for 12 months or more and 10 were not receiving EPO therapy [HD-EPO(-)]. Both groups were not receiving iron supplementation. RESULTS: All parameters, with the exception of MMP-9, were lower in the healthy subjects compared with the HD subjects, irrespective of EPO administration. There was no difference in MMPs/TIMPs system, MDA and C-reactive levels between HD-EPO(+) and HD-EPO(-) patients. CONCLUSION: Erythropoietin therapy did not influence MMPs/TIMPs system, inflammation, or SOX in a low-risk HD patient population, in the absence of concomitant iron supplementation and mean Hg levels within target.


Subject(s)
C-Reactive Protein/metabolism , Erythropoietin/adverse effects , Metalloproteases/drug effects , Oxidative Stress/drug effects , Renal Dialysis/adverse effects , Tissue Inhibitor of Metalloproteinases/drug effects , Adult , Aged , Anemia/drug therapy , Case-Control Studies , Erythropoietin/administration & dosage , Female , Humans , Male , Malondialdehyde/blood , Metalloproteases/blood , Middle Aged , Tissue Inhibitor of Metalloproteinases/blood , Uremia/therapy
18.
Osteoarthritis Cartilage ; 15(5): 531-42, 2007 May.
Article in English | MEDLINE | ID: mdl-17188523

ABSTRACT

OBJECTIVE: To study the effects of the non-steroidal anti-inflammatory drugs (NSAIDs) aceclofenac, piroxicam, tenoxicam and indomethacin on cytokine, matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and prostaglandin E2 (PGE2) production, by interface membranes (IFT), obtained at revision surgery for aseptic loosening of total joint arthroplasty. Involvement of these soluble factors is well documented and probably, a pharmaceutically induced inhibition of them might retard loosening. METHODS: IFTs from 10 patients with a loose hip or knee endoprosthesis were collected. The possibility of septic loosening was thoroughly excluded by histopathologic and microbiologic evaluation. IFTs were cultured in the absence or presence of the tested drugs and the levels of the soluble mediators were determined, using electrophoretic and enzyme-linked immunosorbent assay techniques. Paracetamol was used as neutral drug. RESULTS: All NSAIDs exhibited a pronounced inhibitory effect upon the production of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha). This specific effect on IL-6 is reported in the literature for the first time. The majority of NSAIDs also induced the production of IL-1beta in an adequate portion of samples. These drugs did not have a clear effect on MMP synthesis, but they had a stimulatory tendency on TIMP-1 production. Paracetamol, significantly decreased the synthesis of TNF-alpha and that of the gelatinases. CONCLUSION: Our in vitro results are encouraging, since it appears that the action of NSAIDs, globally considered, may be beneficial upon the loosening process. The inhibitory effect of paracetamol upon TNF-alpha and gelatinases is intriguing. Our data, if supported by similar observations, probably justify performance of long-term clinical trials.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cytokines/drug effects , Matrix Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Aged , Aged, 80 and over , Arthroplasty, Replacement, Hip/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Cytokines/metabolism , Diclofenac/analogs & derivatives , Diclofenac/pharmacology , Dinoprostone/metabolism , Female , Hip Prosthesis/adverse effects , Humans , Indomethacin/pharmacology , Knee Prosthesis/adverse effects , Matrix Metalloproteinases/metabolism , Middle Aged , Piroxicam/analogs & derivatives , Piroxicam/pharmacology , Tissue Inhibitor of Metalloproteinases/metabolism
19.
Arch Oral Biol ; 52(6): 585-90, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17181997

ABSTRACT

OBJECTIVE: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a role in the breakdown of the extracellular matrix during normal physiological processes, and in pathological processes, including periodontitis. The aim of this study was to evaluate the effect of epidermal growth factor (EGF) on the expression of MMPs and TIMPs in cultured human gingival fibroblasts. METHODS: Fibroblasts were stimulated with 10(-3), 10(-6) or 10(-12)M EGF for 24h; untreated fibroblasts served as controls. Alterations in the expression of MMP-1, 2, 3, 7, 11, TIMP-1 and 2 were evaluated using real-time PCR and Western blotting. beta-Actin expression was used as a reference to normalize gene expression. RESULTS: Increased MMP-1, 3, 7 and 11 expressions were observed at all EGF concentrations (p<0.05). At the lowest EGF concentration, MMP-1, 3 and 7 presented the lowest expression and MMP-11 presented the greatest expression; at higher EGF concentrations, MMP-1, 3 and 7 presented greater up-regulation, and MMP-11 lower up-regulation (p<0.05). Protein expression was similarly regulated by EGF: increased up-regulation of MMP-1, 3 and 7 was observed with increasing EGF concentrations, except for MMP-11 that exhibited greater up-regulation at the lower EGF concentration. The gene expression of MMP-2, TIMP-1 and 2 was not affected by EGF (p<0.05). CONCLUSIONS: We conclude that EGF regulates expression for MMP-1, 3, 7 and 11 in a dose-dependent manner, suggesting that EGF may play a role in periodontal destruction and wound repair.


Subject(s)
Epidermal Growth Factor/pharmacology , Fibroblasts/drug effects , Gingiva/drug effects , Matrix Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Fibroblasts/enzymology , Gene Expression Regulation/drug effects , Gingiva/cytology , Gingiva/enzymology , Humans , Matrix Metalloproteinase 1/analysis , Matrix Metalloproteinase 1/drug effects , Matrix Metalloproteinase 11/analysis , Matrix Metalloproteinase 11/drug effects , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 3/analysis , Matrix Metalloproteinase 3/drug effects , Matrix Metalloproteinase 7/analysis , Matrix Metalloproteinase 7/drug effects , Matrix Metalloproteinases/analysis , Tissue Inhibitor of Metalloproteinase-1/analysis , Tissue Inhibitor of Metalloproteinase-1/drug effects , Tissue Inhibitor of Metalloproteinase-2/analysis , Tissue Inhibitor of Metalloproteinase-2/drug effects , Tissue Inhibitor of Metalloproteinases/analysis , Up-Regulation/drug effects
20.
J Rheumatol ; 33(8): 1523-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16881109

ABSTRACT

OBJECTIVE: To analyze serum concentrations of matrix metalloproteinases (MMP) MMP-1, MMP-3, MMP-9, MMP-13, tissue inhibitors of MMP (TIMP) TIMP-1 and TIMP-2, and MMP/TIMP ratios in patients with early rheumatoid arthritis (RA) before and after 6 months of treatment with methotrexate (MTX). METHODS: The study group consisted of 30 patients with RA, not treated with disease modifying antirheumatic drugs or corticosteroids, with disease duration < 3 years. Twenty patients with osteoarthritis (OA) served as a control group. Analysis of serum concentrations of MMP and TIMP was based on a quantitative sandwich ELISA. RESULTS: Serum concentrations of MMP-1, MMP-3, MMP-9, and MMP-13 were higher in untreated patients with early RA than in OA patients (p < 0.001 in all cases). Serum levels of TIMP-1 and TIMP-2 dominated in the serum of RA patients compared with controls (p < 0.01 and p < 0.05, respectively). Ratios of MMP to TIMP were significantly higher in patients with early RA versus controls. Six months' treatment with MTX downregulated serum concentrations of MMP-1 (p < 0.001), MMP-3 (p < 0.001), MMP-9 (p < 0.001), MMP-13 (p < 0.01), and TIMP-1 (p < 0.05) in patients with RA. These changes were accompanied by significantly reduced ratios of MMP to TIMP. MTX treatment decreased markers of RA activity such as the number of painful and swollen joints, erythrocyte sedimentation rate, Disease Activity Score, and C-reactive protein. CONCLUSION: Patients with early RA are characterized by high serum concentrations of tissue-degrading metalloproteinases. Therapy with MTX resulted in clinical improvement and reduced serum MMP levels in patients with RA, confirming effectiveness of MTX in patients in early stages of the disease.


Subject(s)
Arthritis, Rheumatoid/blood , Matrix Metalloproteinases/blood , Tissue Inhibitor of Metalloproteinases/blood , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/physiopathology , Early Diagnosis , Female , Health Status , Humans , Joints/drug effects , Joints/physiopathology , Male , Matrix Metalloproteinases/drug effects , Methotrexate/therapeutic use , Middle Aged , Severity of Illness Index , Tissue Inhibitor of Metalloproteinases/drug effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...